Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Multiple Myeloma × Nivolumab × Clear all

Phase

Status

Sponsor Class

OTHER 14 NIH 3 INDUSTRY 2 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Hodgkin Disease 2 Recurrent Squamous Cell Lung Carcinoma 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Gastric and Esophagogastric Junction Adenocarcinoma 1 Colorectal Neoplasms 1 Carcinoma 1 Advanced Solid Tumors 1 Adenocarcinoma 1

Interventions

Dexamethasone 39 Bortezomib 20 Lenalidomide 17 Cyclophosphamide 17 daratumumab 14 Thalidomide 11 Melphalan 11 Calcium Dobesilate 11 Prednisone 7 carfilzomib 6 Peripheral Blood Stem Cell Transplantation 6 pomalidomide 5 Doxorubicin 5 dexamethasone acetate 4 dexamethasone 21-phosphate 4 auricularum 4 Filgrastim 4 Vincristine 3 Interferon-alpha 3 selinexor 2 sargramostim 2 ixazomib 2 isatuximab 2 elotuzumab 2 cobimetinib 2 Steroids 2 Radiotherapy 2 Microarray Analysis 2 Gene Expression Profiling 2 Etoposide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03297606 2026-03-04

CAPTUR

Canadian Cancer Trials Group

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡